In this Article
Is there any treatment?
The severity and duration of an attack of shingles can be significantly reduced by immediate treatment with antiviral drugs, which include acyclovir, valcyclovir, or famcyclovir. Antiviral drugs may also help stave off the painful after-effects of shingles known as postherpetic neuralgia. Other treatments for postherpetic neuralgia include steroids, antidepressants, anticonvulsants, and topical agents.
What is the prognosis?
For most people, the lesions heal, the pain subsides within 3 to 5 weeks, and the blisters leave no scars. However, shingles is a serious threat in immunosuppressed individuals - for example, those with HIV infection or who are receiving cancer treatments that can weaken their immune systems. People who receive organ transplants are also vulnerable to shingles because they are given drugs that suppress the immune system.
What research is being done?
The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health (NIH) conduct shingles research in laboratories at the NIH and also support additional research through grants to major medical institutions across the country. Current research is aimed at finding new methods for treating shingles and its complications. Beginning in the late 1990s, the Department of Veterans Affairs (VA) conducted a nationwide, multicenter trial to study an experimental vaccine aimed at preventing shingles. The study tested a more potent version of the vaccine currently used to immunize children against the chickenpox virus. At the completion of the study researchers found that the vaccine reduced the incidence of shingles by half. In April 2005 the Food and Drug Administration received a license application from the manufacturer for the zoster vaccine. If approved for use, the vaccine has the potential to prevent hundreds of thousands of cases of shingles in the United States each year. More information about this study is available at http://www.nih.gov/news/pr/jun2005/niaid-01a.htm.
Source: National Institute of Neurological Disorders and Stroke, National Institutes of Health
Last Editorial Review: 3/28/2006